Loading...
Vetoquinol SA
VETO.PA•EURONEXT
HealthcareDrug Manufacturers - Specialty & Generic
$72.90
$-0.20(-0.27%)
Vetoquinol SA (VETO.PA) Stock Overview
Explore Vetoquinol SA’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for VETO.PAStats details for VETO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for VETO.PAAnalyst Recommendations details for VETO.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
CEO
Mr. Alain Masson
Employees
2,519
Headquarters
Magny-Vernois, Lure
Founded
2006